{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:55:56Z","timestamp":1762253756357,"version":"3.44.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.cpcardiol.2021.100859","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T12:32:14Z","timestamp":1617453134000},"page":"100859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Firibastat: A Novel Brain Aminopeptidase Inhibitor \u2013 A New Era of Antihypertensive therapy"],"prefix":"10.1016","volume":"47","author":[{"given":"Rahul","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Alcantara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarun","family":"Popli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umair","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aayaan","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sugandhi","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiwot","family":"Ayele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasotha","family":"Rajeswaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apurva V.","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2021.100859_bib0001","first-page":"1","article-title":"Hypertension prevalence and control among adults: United States, 2011-2014","volume":"220","author":"Yoon","year":"2015","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0002","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/CIRCULATIONAHA.117.032582","article-title":"Potential US Population impact of the 2017 ACC\/AHA high blood pressure guideline","volume":"137","author":"Muntner","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0003","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0004","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0005","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0006","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0007","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Prospective Studies C. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0008","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0009","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0010","first-page":"e18","article-title":"Heart disease and stroke statistics\u20132011 update: a report from the American Heart Association","volume":"123","author":"Roger","year":"2011","journal-title":"Circulation."},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0011","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/HJH.0b013e328353634e","article-title":"Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs","volume":"30","author":"de la Sierra","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0012","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0013","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0014","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijcard.2016.12.158","article-title":"A meta-analysis of add-on use of spironolactone in patients with resistant hypertension","volume":"233","author":"Zhao","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0015","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","article-title":"Resistant hypertension? Assessment of adherence by toxicological urine analysis","volume":"31","author":"Jung","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0016","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/HYPERTENSIONAHA.116.08818","article-title":"Impact of medication adherence on the effect of renal denervation: the SYMPATHY trial","volume":"69","author":"de Jager","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0000000000000065","article-title":"Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension","volume":"32","author":"Weber","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0018","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0019","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0020","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA."},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0021","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0022","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00004872-198801000-00012","article-title":"Increased concentration of angiotensin II binding sites in selected brain areas of spontaneously hypertensive rats","volume":"6","author":"Gutkind","year":"1988","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0023","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1161\/01.HYP.27.6.1216","article-title":"Tissue-specific regulation of angiotensinogen gene expression in spontaneously hypertensive rats","volume":"27","author":"Tamura","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0024","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.RES.83.10.1047","article-title":"The brain renin-angiotensin system contributes to the hypertension in mice containing both the human renin and human angiotensinogen transgenes","volume":"83","author":"Davisson","year":"1998","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev.ph.49.030187.002213","article-title":"Functions of angiotensin in the central nervous system","volume":"49","author":"Phillips","year":"1987","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0026","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1210\/edrv-13-2-329","article-title":"Brain and pituitary angiotensin","volume":"13","author":"Saavedra","year":"1992","journal-title":"Endocr Rev"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0027","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0167-0115(95)00084-O","article-title":"Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions","volume":"59","author":"Wright","year":"1995","journal-title":"Regul Pept"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0028","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0165-0173(92)90018-H","article-title":"Regulatory role of brain angiotensins in the control of physiological and behavioral responses","volume":"17","author":"Wright","year":"1992","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0029","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1073\/pnas.87.3.993","article-title":"Molecular cloning of the murine BP-1\/6C3 antigen: a member of the zinc-dependent metallopeptidase family","volume":"87","author":"Wu","year":"1990","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0030","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1073\/pnas.90.15.7069","article-title":"Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A","volume":"90","author":"Nanus","year":"1993","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0031","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1006\/geno.1993.1386","article-title":"cDNA cloning and expression of human glutamyl aminopeptidase (aminopeptidase A)","volume":"17","author":"Li","year":"1993","journal-title":"Genomics"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0032","doi-asserted-by":"crossref","first-page":"9069","DOI":"10.1074\/jbc.271.15.9069","article-title":"Identification of glutamate residues essential for catalytic activity and zinc coordination in aminopeptidase A","volume":"271","author":"Vazeux","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0033","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0006-291X(89)91586-6","article-title":"Molecular cloning and amino acid sequence of rat kidney aminopeptidase M: a member of a super family of zinc-metallohydrolases","volume":"161","author":"Malfroy","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0034","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1016\/S0021-9258(18)83570-0","article-title":"Amino acid sequence deduced from a rat kidney cDNA suggests it encodes the Zn-peptidase aminopeptidase N","volume":"264","author":"Watt","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0035","doi-asserted-by":"crossref","first-page":"11968","DOI":"10.1073\/pnas.93.21.11968","article-title":"Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release","volume":"93","author":"Zini","year":"1996","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0036","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000054439","article-title":"PC18, a specific aminopeptidase N inhibitor, induces vasopressin release by increasing the half-life of brain angiotensin III","volume":"69","author":"Reaux","year":"1999","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0037","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/jm00085a013","article-title":"Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation","volume":"35","author":"Fournie-Zaluski","year":"1992","journal-title":"J Med Chem"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0038","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1021\/jm00035a014","article-title":"Investigation of the active site of aminopeptidase A using a series of new thiol-containing inhibitors","volume":"37","author":"Chauvel","year":"1994","journal-title":"J Med Chem"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0039","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/00001756-199803300-00011","article-title":"Inhibition of vasopressinergic neurons by central injection of a specific aminopeptidase A inhibitor","volume":"9","author":"Zini","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/FJC.0000000000000638","article-title":"Specific inhibition of brain angiotensin III formation as a new strategy for prevention of heart failure after myocardial infarction","volume":"73","author":"Leenen","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0041","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1073\/pnas.0402312101","article-title":"Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension","volume":"101","author":"Fournie-Zaluski","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0042","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1021\/jm00091a016","article-title":"Mixed inhibitor-prodrug\" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes","volume":"35","author":"Fournie-Zaluski","year":"1992","journal-title":"J Med Chem"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0043","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/HJH.0000000000001563","article-title":"Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats","volume":"36","author":"Marc","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0044","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1161\/HYPERTENSIONAHA.107.098772","article-title":"Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension","volume":"51","author":"Bodineau","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0045","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.112.190942","article-title":"Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats","volume":"60","author":"Marc","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0046","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.119.040070","article-title":"Efficacy and safety of firibastat, a first-in-class brain aminopeptidase a inhibitor, in hypertensive overweight patients of multiple ethnic origins","volume":"140","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0047","first-page":"1","article-title":"Prevalence of obesity among adults and youth: United States, 2015-2016","volume":"288","author":"Hales","year":"2017","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0048","first-page":"1","article-title":"Hypertension prevalenceand control among adults: United States, 2015-2016","volume":"289","author":"Fryar","year":"2017","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0049","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12049","article-title":"Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension","volume":"15","author":"Landsberg","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0050","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/HJH.0000000000000204","article-title":"Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT","volume":"32","author":"Reisin","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0051","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.293.13.1595","article-title":"Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril","volume":"293","author":"Wright","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0052","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pcad.2019.12.008","article-title":"The NEW-HOPE study and emerging therapies for difficult-to-control and resistant hypertension","volume":"63","author":"Ferdinand","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0053","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1097\/HJH.0000000000002092","article-title":"A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension","volume":"37","author":"Azizi","year":"2019","journal-title":"J Hypertens"},{"year":"2020","series-title":"A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat\/Resistant Hypertensive Subjects (Clinical Trial Registration No. NCT04277884)","key":"10.1016\/j.cpcardiol.2021.100859_bib0054"},{"key":"10.1016\/j.cpcardiol.2021.100859_bib0055","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/cvr\/cvs420","article-title":"Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction","volume":"97","author":"Huang","year":"2013","journal-title":"Cardiovasc Res"},{"year":"2020","key":"10.1016\/j.cpcardiol.2021.100859_bib0056"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280621000748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280621000748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:59:42Z","timestamp":1758938382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280621000748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0146280621000748"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100859","relation":{},"ISSN":["0146-2806"],"issn-type":[{"type":"print","value":"0146-2806"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Firibastat: A Novel Brain Aminopeptidase Inhibitor \u2013 A New Era of Antihypertensive therapy","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"100859"}}